Wednesday, January 27, 2010
glamour model Michelle Marsh
Despite numerous published studies by government scientists and university laboratories that raised health concerns about bisphenol A (BPA) exposure, the U.S. Food and Drug Administration (FDA) has yet to act to tighten safety standards. The agency declared the chemical safe even after a 2008 toxicology report from the National Institutes of Health (NIH) said there was cause for “some concern” for BPA’s potential effects on the brain, behavior and prostate in developing fetuses, infants and children. But on Friday, the FDA shifted their long-held stance, saying it now supports the toxicology assessment of BPA and feels the issue merits further study—stopping short of calling for restrictions on its use.
“We are for the first time saying we believe there is some concern about the substance’s safety, and we’ve closed the gap between NIH and FDA,” Deputy FDA Commissioner Dr. Josh Sharfstein told reporters. He said the agency was also re-evaluating the way it regulates BPA, hoping to change its status to one that would give the FDA more power to make more timely regulatory changes if they need to.
The National Institute of Environmental Health Sciences (NIEHS) has been allotted $30 million to further access the health effects of BPA. The Institute’s director, Dr. Linda Birnbaum, said the research program would focus on potential effects on behavior, diabetes, reproductive disorders, development of certain types of cancer, asthma, heart disease and effects that could be carried from one generation to the next. Officials say the research will likely be completed in 18 to 24 months.